1. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer
- Author
-
Giannino Del Sal, Andrea Bisso, Reuven Agami, Libero Santarpia, Jacopo De Santa, Silvano Piazza, Valeria Capaci, Federico Zampa, M. G. Daidone, Michela Faleschini, Vera Cappelletti, Bisso, Andrea, Faleschini, Michela, Zampa, F, Capaci, Valeria, DE SANTA, Jacopo, Santarpia, L, Piazza, S, Cappelletti, V, Daidone, M, Agami, R, and DEL SAL, Giannino
- Subjects
DNA Repair ,DNA damage ,DNA repair ,Breast Neoplasms ,Biology ,DNA damage response ,Ataxia Telangiectasia Mutated Proteins ,Breast cancer ,PARP1 ,breast cancer ,RNA interference ,Report ,microRNA ,medicine ,BRCAness ,Humans ,Molecular Biology ,PARP inhibitors ,ATM ,BRCA1 ,Kinase ,Cell Biology ,medicine.disease ,3. Good health ,MicroRNAs ,PARP inhibitor ,BRCAne ,Cancer research ,Female ,Developmental Biology - Abstract
Breast cancer is a heterogeneous tumor type characterized by a complex spectrum of molecular aberrations, resulting in a diverse array of malignant features and clinical outcomes. Deciphering the molecular mechanisms that fuel breast cancer development and act as determinants of aggressiveness is a primary need to improve patient management. Among other alterations, aberrant expression of microRNAs has been found in breast cancer and other human tumors, where they act as either oncogenes or tumor suppressors by virtue of their ability to finely modulate gene expression at the post-transcriptional level. In this study, we describe a new role for miR-181a/b as negative regulators of the DNA damage response in breast cancer, impacting on the expression and activity of the stress-sensor kinase ataxia telangiectasia mutated (ATM). We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers, and their expression correlates inversely with ATM levels. Moreover we demonstrate that deregulated expression of miR-181a/b determines the sensitivity of triple-negative breast cancer cells to the poly-ADP-ribose-polymerase1 (PARP1) inhibition. These evidences suggest that monitoring the expression of miR-181a/b could be helpful in tailoring more effective treatments based on inhibition of PARP1 in breast and other tumor types.
- Published
- 2013